Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Accuredit and N1 Life Form JV to Develop Gene Editing Delivery Technologies

publication date: Jan 13, 2022

Accuredit Therapeutics (Suzhou) formed a JV with N1 Life of San Jose, CA to develop gene editing therapies. The JV, Napoltec Life Sciences (Suzhou), will develop novel therapeutic drug delivery systems to advance drug candidates toward clinical translation. Founded in 2021, Accuredit focuses its novel gene editing delivery technologies on intracellular targets. N1 Life, another new company, also develops cutting edge drug delivery technologies. Its technology comes from the innovative drug delivery research lab of Professor Paul A. Wender, Francis W. Bergstrom Professor of Chemistry & Chemical & System Biology at Stanford. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital